Coronavirus Disease-2019 Vaccine Hesitancy

E Adrianne Hammershaimb; James D Campbell; Sean T O'Leary

doi:10.1016/j.pcl.2022.12.001

Coronavirus Disease-2019 Vaccine Hesitancy

Pediatr Clin North Am. 2023 Apr;70(2):243-257. doi: 10.1016/j.pcl.2022.12.001. Epub 2022 Dec 8.

Authors

E Adrianne Hammershaimb¹, James D Campbell¹, Sean T O'Leary²

Affiliations

¹ Division of Infectious Diseases and Tropical Pediatrics, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA; Center for Vaccine Development and Global Health, University of Maryland, School of Medicine, Health Sciences Research Facility 1, Research Facility 1, Room 480, 685 West Baltimore Street, Baltimore, MD 21201, USA.
² Department of Pediatrics, University of Colorado Anschutz Medical Campus, F443, 1890 North Revere Court, Aurora, CO 80045, USA. Electronic address: SEAN.OLEARY@CUANSCHUTZ.EDU.

Abstract

Early in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, before coronavirus disease-2019 (COVID-19) vaccines were authorized, surveys began tracking public acceptance of a hypothetical COVID-19 vaccine. As vaccines became more widely available, the focus shifted from evaluating premeditative thoughts about COVID-19 vaccines to observing behaviors, measuring uptake, and characterizing factors associated with acceptance. A wealth of peer-reviewed literature examining the complexities of COVID-19 vaccine acceptance has emerged, but our understanding of COVID-19 vaccine acceptance is constantly evolving. In this article, we review the current state of knowledge regarding COVID-19 vaccine hesitancy, with an emphasis on pediatric vaccination.

Keywords: COVID-19; Children; Pandemic; Pediatric; SARS-CoV-2; Vaccination; Vaccine; Vaccine hesitancy.

Publication types

Review

MeSH terms

COVID-19 Vaccines*
COVID-19*
Child
Humans
SARS-CoV-2
Vaccination
Vaccination Hesitancy

Substances

COVID-19 Vaccines

Grants and funding

T32 AI007524/AI/NIAID NIH HHS/United States